The German Federal Association of the Pharmaceutical Industry (BPI) have released a statement on their website regarding the effect of Brexit on the German healthcare system and the preparations being made for a ‘no-deal’ Brexit. A previous MAP BioPharma news article on the effect of Brexit on the German healthcare system is available here.
In terms of the movement of medicines, vaccines and medical devices the BPI have stated that there are currently no concrete indications that Brexit will lead to serious problems with their supply in Germany. In the case of a withdrawal agreement goods will continue to be allowed to be traded. In the case of a ‘no-deal’ Brexit the BPI believes bottlenecks can be avoided if pharmaceutical and medical device companies take responsibility in good time.
As the Professional Recognition Directive 2005/36/EC will no longer apply after Brexit, an exit agreement has been created for recognition of professional qualifications for health professionals. In the case of a ‘no-deal’ Brexit the BPI has stated the recognition of qualifications in the health professions of EU citizens in Great Britain is unclear, as this depends on the national regulations in Britain. For professional recognition in Germany of British diplomas acquired after Brexit, the general recognition arrangements for third-country nationals would apply, so affected citizens are requested to submit their application for recognition as early as possible and in good time before 29 March 2019.